Internationale Zeitschrift für Physikalische Medizin und Rehabilitation
Offener Zugang
ISSN: 2329-9096
ISSN: 2329-9096
Kauê Cézar Sá Justo, Aguinaldo Bonalumi FIlho, Fernando Henrique Teixeira Zonzini, Jessica Scherer Dagostini, Adriane Reichert Faria, Anber Ancel Tanaka, Michel Fleith Otuki*
Psoriasis is a chronic inflammatory skin disease with multisystem involvement and associated with multiple comorbidities. It is estimated that the disease affects up to 11.4% of adults. Several factors contribute to the development and worsening of psoriasis and the identification of these factors is important to individualize therapy and achieve better therapeutic results and the quality of life for these patients. However, epidemiological data are scarce, especially in Brazil, making clinical management difficult. The aim of the Pso.BRA study is to trace the pharmacoepidemiological profile of patients with psoriasis in Brazil. The pilot project included 97 patients over 18 years of age, of both sexes, with psoriasis diagnosed at any level of severity treated at two outpatient psoriasis services located in Curitiba (Paraná, Brazil). Regarding sociodemographic data, the mean age of patients was 55.93, with predominance of males and Caucasian. The mean age of psoriasis onset in the participants was 37, and about half of the patients reported having a family member with psoriasis. The mean number of attacks per year was 1.51, and the psoriasis severity rating was 4.33. Around 23.7% reported dissatisfaction with treatment. Pruritus was highlighted as the greatest discomfort among patients. There was a predominance of obesity, sedentary lifestyle, and altered abdominal circumference, as well as arterial hypertension, diabetes, and high cholesterol, when compared to data from the general Brazilian population. All these associated factors bring an extra cardiovascular risk to patients and these conditions must be analyzed individually in search of control of psoriasis and comorbidities. The continuity of the study will bring data that will determine the pharmacoepidemiological profile of Brazilian patients, significantly impacting decision-making for the treatment and control of both psoriasis and associated comorbidities.